Betty C. Pang
Partner
San Francisco
betty.pang@lw.com
+1.415.395.8130
PRACTICES
- Corporate Governance
- Emerging Companies & Growth
- Healthcare Regulatory
- White Collar Defense & Investigations
INDUSTRIES
- Healthcare & Life Sciences
EDUCATION
- MD, Stanford University, 2005
- JD, Harvard Law School, 2003
- BA, Stanford University, 1998
- BS, Stanford University, 1998
LANGUAGES SPOKEN
PROFILE
Dr. Betty Pang advises clients in the healthcare and life sciences industry on regulatory matters and corporate transactions.
Betty brings a comprehensive view of the industry to advise clients on complex and sensitive issues pertaining to:
- Fraud and abuse
- Self-referral and government program reimbursement compliance
- Facility and provider licensing
- Corporate practice and fee-splitting
She represents a full spectrum of clients in the healthcare ecosystem, including:
- Hospitals and health systems
- Physician practice management companies and affiliated practices
- Clinical laboratory and diagnostic service providers
- Telehealth, digital health and wellness companies
- Life science companies, including pharmaceutical, medical device, biotechnology, and medical suppliers
- Private equity firms
- Investment banks
With a seasoned understanding of the industry drawn from prolific deal flow, and a complementary understanding of the scientific and medical issues drawn from her medical degree, she efficiently and effectively support clients through:
- Mergers and acquisitions
- Initial public offerings
- Financings
- Joint ventures
- Government investigations
- Day-to-day regulatory and compliance issues
Betty has focused her entire career on the healthcare and life sciences industry, and is a member of the American Health Lawyers Association, the California Society for Healthcare Attorneys, and the American Bar Association Health Law Section. She serves as a Bay Area Local Office Leader for Latham’s Asian and Middle Eastern Lawyers Group and has served as an advisor for the firm’s Diversity Scholars Program.
EXPERIENCE
Regulatory clients include:
- Ceribell
- Cerula Care
- Eargo
- Eleusis
- Elevar Therapeutics
- Galen Healthcare
- Health Outlook
- Healthy Longevity Clinic
- Inari
- Neuralink
- Oscar Health
- P3 Health Partners
- Perry Health
- Praxis Precision Medicines
- RIPPL Care
- Tenet
- The Cooper Companies
- The Oncology Institute
Betty's transactional work includes:
Capital Markets
- Aimmune Therapeutics in its US$160 million initial public offering
- Aligos Therapeutics in its US$173 million initial public offering
- Angion Biomedical in its US$117 million initial public offering
- Arcutis Biotherapeutics in its US$183 million common stock offering
- Ascendis Pharma in its US$500 million initial public offering and subsequent US$500 million convertible notes offering
- Corvus Pharmaceuticals in its US$60 million follow-on offering
- CytomX Therapeutics in its US$116.9 million initial public offering and follow-on offering
- Gritstone Oncology in its US$74.8 million offering
- Imago BioSciences in its US$134.4 million initial public offering
- Oscar Health in its US$1.44 billion initial public offering
- Prometheus Biosciences in its US$218 million initial public offering
- Prothena in its US$72.6 million offering
- Revolution Medicines in its:
- US$230 million public offering
- US$300 million common stock offering
- Rhythm Pharmaceuticals in its US$172 million common stock offering
- Sana Biotechnology in its US$675 initial public offering
- Teladoc in its US$180 million initial public offering
- Numerous underwriters in various offerings, including:
- Aclaris Therapeutics’ US$25 million at-the-market offering
- Alpine Immune Sciences' US$100 million public offering
- Aspira Women’s Health’s US$52 million common stock offering
- Chinook Therapeutics’ US$105 million public offeringEliem Therapeutics’ initial public offering
- Halozyme Therapeutics’ US$700 million convertible senior notes offering
- Instil Bio’s US$320 million initial public offering
- Minerva Surgical’s US$75 million initial public offering
- Petco’s US$279 initial public offering
- Sientra’s US$42 million common stock offering
- Vor Biopharma’s US$203 million initial public offering
Mergers and Acquisitions
- Bonti in its US$195 million sale to Allergan
- CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
- Eleusis in its US$446 million business combination with Silver Spike Acquisition Corp.
- IIImago BioSciences in its pending US$1.35 billion acquisition by Merck
- Khosla Ventures Acquisition Co. in its US$2.25 billion business combination with Valo Health
- KKR in its:
- US$1.4 billion acquisition of PharMerica
- US$354 million acquisition of Covenant Surgical Partners
- Leonard Green & Partners L.P. in its US$363 million acquisition of Prospect Medical Holdings
- North American Science Associates (NAMSA) in its US$43.5 million acquisition of American Preclinical Services, LLC
- Pionyr Immunotherapeutics in its US$275 million sale to Gilead Sciences
- Preventice Solutions in its US$1.23 billion sale to Boston Scientific
Finance
- Bank of America and Merrill Lynch, Fenner, Pierce & Smith in the US$3 billion term loan and revolving credit facilities in connection with Gilead Science’s US$11.2 billion acquisition of Pharmasset, a clinical stage pharmaceutical company focused primarily on developing oral therapeutics for the treatment of hepatitis C
- Deutsche Bank in the incremental term loan and revolving credit facility in connection with Endo Limited's acquisition of Par Pharmaceutical Holdings, a specialty pharmaceutical company
- Innocoll Biotherapeutics in its US$125 million term loan provided by funds managed by Oaktree Capital
- JPMorgan in the:
- US$3.65 billion term loan and revolving credit facility for PPD, a global contract research organization that provides drug discovery, clinical development, lifecycle management, and laboratory services, to refinance existing debt
- US$38.3 billion term loan facilities in connection with Takeda Pharmaceutical Company Limited’s acquisition of Shire plc, an Ireland-based biopharmaceutical company
- SLR Capital Partners in the US$300 million debt facilities for Outset Medical